Expanded Use of TIMI Risk Score for CV Event Prediction in Diabetes
The TIMI Risk Score provides a practical risk assessment tool for patients with type 2 diabetes.
Certain SGLT2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate significant cardiovascular benefits.
The addition of ezetimibe to simvastatin reduced ischemic risk compared with placebo, with consistent relative risk reductions in patients with and without polyvascular disease.
The American College of Cardiology published an expert consensus statement regarding decision considerations for novel cardiovascular risk reduction therapies in patients with type 2 diabetes and atherosclerotic cardiovascular disease.